Immune Age Revisited: New 2026 Biomarkers Reveal Sex-Specific Biological Decline
From Chronological to Cellular: The Rise of Immune Aging Clocks The landscape of biological age estimation has undergone a fundamental recalibration this spring...
Discover insightful articles on health, wellness, and the habits that support a longer, stronger life.
Showing 13 to 24 of 34 articles
From Chronological to Cellular: The Rise of Immune Aging Clocks The landscape of biological age estimation has undergone a fundamental recalibration this spring...
The Dont Die Blueprint protocol that is free and available for everyone online to follow the perfect human diet. Review its research ground and discuss the viability for most people.
Oral Senolytics Step Out of the Lab: Phase II Trial Shows Fisetin Mitigates Physical Impairment The landscape of geroscience is undergoing a structural shift, m...
A Precise Pivot in Longevity Research As of mid-May 2026, the geroscience landscape is undergoing a quiet but decisive transition. While earlier phases of longe...
From Cellular Clearance to Tissue Protection For years, the geroscience community has operated under a straightforward therapeutic premise: if aging cells drive...
The 2026 Paradigm Shift: From Broad Action to Molecular Fidelity As the geroscience field enters mid-2026, a distinct evolution is reshaping how researchers app...
Beyond HbA1c: How Glucose Variability Accelerates Vascular Aging For years, metabolic health assessments have leaned heavily on static metrics like hemoglobin A...
The Muscle Paradox: GLP-1 Therapy, Lean Mass Loss, and Emerging Skeletal Risks While GLP-1 receptor agonists such as semaglutide and tirzepatide remain dominant...
Why 2026 is a turning point for getting geroscience therapies to older adults As of May 12, 2026, developers of therapies aimed at aging biology face a regulato...
Why the induction method matters Life Biosciences’ ER‑100, the first partial‑reprogramming therapy to receive an FDA IND, uses a doxycycline‑inducible system to...
Summary In early 2026 Life Biosciences received FDA clearance of an IND for ER‑100, opening a Phase 1, first‑in‑human, single‑dose safety trial in open‑angle gl...
Why different geroscience tools demand different trials The partial epigenetic reprogramming approach represented by ER‑100 (AAV2‑delivered OSK) and two classes...
Join the mailing list
Be the first to know when fresh articles are published.